HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Appeals Industry Self-Regulation Forum’s Finding Against Benefiber ‘100% Natural’ Claim

Executive Summary

GSK will appeal a finding that it doesn’t support its “100% Natural” claim for Benefiber Original and Healthy Shape. Question asked in the review from a P&G challenge reflects FDA’s ongoing consideration of whether a public health concern will emerge if it doesn’t substantially expand its regulation of use of the term.

You may also be interested in...



GSK's Benefiber Constipation-Relief Claim Supported In Review Following P&G Challenge

GSK supported claim Benefiber Healthy Balance supplement "helps relieve occasional constipation and abdominal discomfort without causing diarrhea" in challenge by Metamucil marketer P&G. Dispute decided in industry self-regulation form focused on PHGG's mechanism of action in reliving constipation.

Pepto-Bismol Ultra Works As Name But Not For P&G To Claim Twice Original Product's Strength

To understand how Pepto-Bismol Ultra could be considered twice as strong as original as stated on packaging, consumers would need to "carefully review the Drug Facts on the back of both" products and "recognize that the active ingredient in both products is 525 mg of bismuth subsalicylate" but Ultra's dose is half original's.

Citrucel Claim That Metamucil Causes Excess Gas Expelled After 20 Years

GlaxoSmithKline will discontinue claim P&G's Metamucil product causes excess gas and it Citrucel doesn't after P&G presented evidence that met NAD's standard for reopening a review. The industry self-regulation organization found GSK could no longer support its claim.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS150062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel